As an extension of our already well-established series of KRAS and BRAF StripAssays, the new BRAF 600/601 StripAssay has being released.
BRAF testing became a focus of interest after the European and American regulatory agencies EMEA and FDA recently approved Vemurafenib (Zelboraf/Roche) as therapeutic drug for the treatment of metastatic melanoma. Vemurafenib is a potent BRAF inhibitor and is only effective in patients carrying a mutation at BRAF codons 600/601. In addition to Vemurafenib, other still experimental drugs targeting mutated BRAF, such as Dabrafenib, are likely to enter the market in the near future.
The BRAF 600/601 StripAssays covers nine BRAF mutations at 1% sensitivity: V600A, V600D, V600E (c.1799T>A), V600E (c.1799_1800TG>AA), V600G, V600K, V600M, V600R, K601E.
For more information visit our webpage at www.viennalab.com